Therefore, our data demonstrate that APG-115 as a single agent is highly effective in reducing the leukemic burden and prolonging survival of mice bearing AML in vivo, and FLT3mut AML cells may be more sensitive to MDM2 inhibitors compared to wild-type FLT3. Here, FLT3 is linked to acute myeloid leukemia.